Taken together, these data demonstrate that the addition of VPA to standard chemotherapy plus anti-VEGF treatment provided a significant antitumor benefit in different RAS/BRAF-mutated CRC in vivo models. The gene discussed is BRAF; the disease is colorectal carcinoma.